The firm is projecting COVID-19 testing revenues of $865 million in the recently completed quarter, including $685 million in Veritor immunoassay sales.
The company brought in $20.2 million during the quarter, driven by strong biopharma revenue, with orders increasing for both its core services and new liquid biopsy offering.
CareDx expects fourth quarter revenues of $58.4 million to $58.6 million, an increase of approximately 63 percent compared to $35.8 million in Q4 2019.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.